Accuracy of early detection of colorectal tumours using stool methylation markers: A meta-analysis

Table 2 Methylation of pooled genes for the diagnosis of colorectal cancer

Wnt pathway	DNA damage repair pathway	Other pathways	SE (95%CI)	SP (95%CI)	DOR (95%CI)	AUC
Wnt pathway	DNA damage repair pathway	Other pathways	73% (0.71-0.75)	92% (90%-93%)	30.86 (22.33-42.66)	0.929
Wnt pathway	-	-	74% (70%-77%)	93% (90%-95%)	33.92 (17.73-64.90)	0.932
-	DNA damage repair pathway	-	42% (36%-47%)	97% (94%-99%)	12.87 (5.98-27.72)	0.730
-	-	Other pathways	57% (55%-60%)	94% (93%-95%)	20.93 (15.56-28.15)	0.921
SFRP2	-	-	79% (75%-82%)	93% (90%-96%)	47.57 (20.08-112.72)	0.957
-	MGMT	-	47% (40%-53%)	95% (90%-98%)	11.67 (5.10-26.67)	0.709
-	MLH	-	28% (18%-39%)	100% (95%-100%)	23.68 (3.02-185.44)	0.500
-	-	Vimentin	48% (42%-54%)	93% (90%-95%)	14.95 (8.99-24.84)	0.862
-	-	OSMR	47% (40%-54%)	95% (91%-98%)	14.66 (5.06-42.47)	0.225
-	-	P16	50% (42%-58%)	98% (92%-100%)	24.39 (7.26-81.96)	0.975
SFRP2	MGMT	-	69% (66%-72%)	94% (91%-96%)	33.24 (16.76-65.93)	0.946
SFRP2	MLH	-	72% (68%-75%)	94% (92%-96%)	43.03 (20.15-91.87)	0.953
SFRP2	MLH	Vimentin	64% (61%-67%)	94% (92%-95%)	27.11 (16.48-44.61)	0.934
SFRP2	MLH	OSMR	65% (62%-69%)	95% (93%-96%)	33.10 (17.12-63.98)	0.951
SFRP2	MLH	P16	68% (64%-71%)	95% (93%-97%)	38.86 (20.11-67.54)	0.952

SE: Sensitivity; SP: Specificity; DOR: Diagnostic odds ratio; AUC: The area under the curve.